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Background: Lactate levels within tumors are correlated with metastases, tumor recurrence, and radioresistance,
thus apparently contributing to poor outcomes in patients with various cancers. We previously reported that
high-level production of lactate by multiple myeloma (MM) cell lines is associated with high-level LDH activity
within such MM cells. However, the kinetics of lactate remains to be studied. In the present study, we attempted
to elucidate the mechanism of lactate incorporation into MM cells.
Methods: Six MM cell lines and stromal cells obtained through long-term culture of bone marrow samples from
MM patients were employed. Incorporation of lactate was quantified using C14-labeled lactate. The role of MCT1, a
member of the monocarboxylate transporters (MCTs), expressed on MM cells, was examined in the presence of its
inhibitor (α-cyano-4-hydroxycinnamic acid: CHC) and by using gene-silencing technique.
Results: MM cell lines as well as stromal cells were found to produce lactate. Incorporation of C14-labeled lactate
into MM cells occurred in all 6 MM cell lines analyzed. Inhibition of MCT1 by using CHC or MCT1-targeting siRNA
reduced lactate incorporation and caused apoptosis in MM cells. This apoptosis was enhanced when the activity of
pyruvate dehydrogenase kinase was blocked by dichroloacetate. Survival of normal peripheral blood mononuclear
cells was not influenced by MCT1 inhibition.
Conclusions: The present data suggest that lactate is produced by MM cell lines and stromal cells, and contributes to
the survival of such MM cells in autocrine or paracrine manners. Suppression of lactate incorporation by targeting
MCT1 may provide a novel therapeutic strategy for MM which may be applicable for other B-cell neoplasms.
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It has been reported that the growth of certain cancer
cells is dependent on aerobic glycolysis to obtain ATP
efficiently via glycolysis under hypoxic conditions, ultim-
ately leading to the production of lactate by cancer cells
[1]. It has also been reported that elevated lactate levels
within tumors are correlated with the incidence of me-
tastases [2,3], tumor recurrence, radioresistance [4], and
poor prognosis [5].* Correspondence: hata@kumamoto-u.ac.jp
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unless otherwise stated.Lactate is transported through monocarboxylate trans-
porters (MCTs), which are composed of 14 members
and encoded by the SLC16 gene family. Among the
MCTs, only four isoforms (MCT1–MCT4) are known as
proton-linked transporters. MCT1 has a superior affinity
for lactate compared with MCT4, and therefore MCT1
is considered to facilitate lactate uptake, whereas MCT4
is considered to export lactate from inside cells [5-8].
The functional expressions of MCT1 and MCT4 are reg-
ulated by CD147 (basigin), which is essential for traffick-
ing and anchoring MCTs in plasma membranes [9-11].
MCT1 is expressed in most tissues and various cancer
cells (e.g., colon, breast, lung, prostate, stomach) [5,12],l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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resulting in cell death [13].
We previously reported that genes related to aerobic
glycolysis are upregulated in MM cells, and that myeloma
cells produce large amounts of lactate in correlation with
expression of the LDH gene [14]. However, accumulating
evidence indicates that lactate produced by cancer cells is
incorporated into the cancer cells themselves as a fuel for
oxidative phosphorylation [15,16]. Doherty [16] et al. re-
ported that lactate is produced by stromal cells and sup-
plied to oxidative cancer cells, which is known as the
reverse Warburg effect. Similar finding was reported in
diffuse large B-cell lymphoma by Martinez et al., showing
that production of lactate from lymphoma associated
stroma cells and lactate incorporation to lymphoma cells
[17]. These previous reports strongly indicate that lactate
is not an energy waste, but instead is actively incorporated
into cells and contributes to the survival of solid tumors
or B-cell neoplasms. However, to date, there have been no
reports showing the incorporation of lactate into myeloma
cells. Thus, in the present study, we investigated the kinet-
ics of lactate in myeloma cells and its importance for the
survival of myeloma cells.
Results
Expression of lactate transporters and lactate
incorporation into MM cells
Expressions of MCT1 and CD147 were detected at various
levels in myeloma cell lines by western blotting (Figure 1A
and B). Analyses of lactate incorporation into myeloma
cells showed that lactate was indeed incorporated into all
myeloma cell lines at various levels (Figure 1C).
Next, we analyzed how lactate was incorporated into
myeloma cells. To elucidate the contribution of MCT1
to lactate incorporation, the expressions of MCT1 or
CD147 were inhibited by siRNA transfection (Figure 2A
and B). MCT1 knockdown led to a significant reduction
in lactate incorporation, while CD147 knockdown did not
result in a reduction in lactate incorporation (Figure 2C),
suggesting a contribution of MCT1 to lactate incorpor-
ation into myeloma cells.
MCT1 inhibition induces apoptosis
Because we found that lactate was incorporated into
myeloma cells, we hypothesized that incorporated lactate
may serve as an energy resource for myeloma cells, and
therefore that myeloma cells may undergo apoptosis
when there is a shortage of lactate within the cells. To
prove this hypothesis, we used CHC, a competitive inhibi-
tor of MCT1, to investigate whether it induces apoptosis
in myeloma cell lines by inhibiting lactate incorporation.
As expected, CHC induced apoptosis in a dose-dependent
manner (Figure 3A). However, CHC did not show cyto-
toxicity toward normal peripheral blood mononuclearcells (PBMCs) (Figure 3B). We confirmed the cytotoxic
activity of CHC toward myeloma cells isolated from MM
patients and found significant induction of apoptosis
by CHC (Figure 3C). Subsequently, we utilized MCT1-
knockdown cells to further confirm the role of MCT1 in
the survival of myeloma cells. As shown in Figure 3D, sig-
nificant induction of apoptosis was found upon MCT1
mRNA inhibition. However, CD147 knockout did not
contribute to apoptosis (data not shown).
Increased cytotoxic effect of CHC with a glycolysis inhibitor
Next, we investigated the effect of combined treatment of
DCA, which theoretically reduces lactate production by
inhibiting pyruvate dehydrogenase kinase, with CHC. We
considered that the combination of DCA with CHC should
accelerate lactate reduction within myeloma cells and
eventually lead to enhancement of apoptosis. As expected,
this combined treatment caused a significant increase in
apoptosis in the myeloma cell line KMM-1 (Figure 4).
Discussion
We previously reported that aerobic glycolysis is oper-
ational in myeloma cells [14] and observed that signifi-
cant amounts of lactate were produced by myeloma cells
as a result of glycolysis. However, lactate is not a wasted
metabolite, but can be considered as an important
energy source for cancer cells [6,15,16,18,19]. Doherty
et al. [16] reported that lactate is supplied to cancer cells
from the surrounding environment, and referred to this
phenomenon as the reverse Warburg effect. We have
shown that lactate was clearly incorporated into mye-
loma cells and that this incorporation was mediated
by MCT1. We also observed production of lactate by
bone marrow stromal cells (data not shown), suggesting
that the reverse Warburg effect might be applied to
the microenvironment in MM as previously reported in
B-cell lymphoma [17]. Taking these hypotheses together,
we further suggest that lactate may serve as an autocrine
energy resource, because it is both produced and incor-
porated by myeloma cells (Figure 5).
However, the mechanisms that regulate lactate kinetics
are still not well established. We found that CD147 knock-
down did not influence lactate uptake or induce apoptosis,
suggesting that CD147 is not required for lactate kinetics.
Additionally, we found that MCT1 knockdown decreased
lactate uptake, and thus consider that lactate is incorpo-
rated by MCT1, but not through CD147. However, other
investigators reported that both CD147 and MCT1 are re-
sponsible for proliferation of myeloma cells and export-
ation of lactate [13], suggesting that the exact roles of
these molecules in lactate transport remain controversial.
Given the accumulation of reports showing MCT1 ex-
pression in various cancer cells (e.g. breast, colon, and
lung cancer) and its correlation with poor prognosis
Figure 1 Analysis of lactate transporters and lactate kinetics in myeloma cell lines. (A) Western blot analyses of MCT1 and CD147. MCT1 and
CD147 are found in all cell lines at various levels. (B) Densitometry analysis of MCT1. The staining intensities of MCT1 in (A) were quantified by
comparison with actin. (C) Incorporation of lactate into myeloma cell lines. The amounts of 14C-lactate in myeloma cells were quantified. Lactate
is clearly incorporated into all myeloma cell lines.
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should play an important role for the survival of mye-
loma cells. Walters et al. [13] also reported that MCT1
mRNA expression levels were significantly higher in
MM plasma cells than MGUS plasma cells, and that
MCT1 expression was correlated with resistance to
chemotherapy. Because MCT1 was reported to be regu-
lated by c-Myc in some cancer cells [22-25], and MYC
dysregulation was caused by complex translocation or
insertion as a late progression event in MM, MCT1
could be induced in advanced MM under the control of
c-Myc. Given that MCT1 could be an adverse prognostic
factor, we consider that MCT1 could be a good thera-
peutic target for advanced MM.
CHC, a competitive inhibitor for MCT1, was reported
to show anticancer effects in various cancer cells
[15,26-28]. In a previous report, CHC was found to in-
hibit mitochondrial respiration and decrease cell growth
through inhibition of cellular pyruvate uptake [29]. Zhaoet al. [26] reported that CHC suppressed tumor growth
of osteosarcoma in vitro and in vivo through regulation
of the NF-kB pathway. Moreover, they reported that
CHC enhanced the efficacy of conventional chemothera-
peutic agents. Another report showed that CHC contrib-
uted to chemosensitization against cisplatin in a colon
cancer cell line [28]. However, there are no reports show-
ing antitumor effects of CHC for myeloma cells. In this
study, CHC induced apoptosis in myeloma cells, but did
not exhibit cytotoxicity toward normal PBMCs, indicating
that MCT1 could be a safe therapeutic candidate mol-
ecule. Moreover, because we found augmentation of cyto-
toxicity by CHC with DCA, cooperative inhibition of the
glucose metabolic pathway could be a useful option.
Our results indicate that modification of lactate kinet-
ics, such as targeting of MCTs by antibody-based che-
motherapeutic reagents, could be an attractive modality
to control the growth of myeloma cells although the tar-
get of this modality may be limited for some subsets of
Figure 2 Knockdown of MCT1 induces apoptosis and reduces lactate incorporation. (A, B) MCT1 (A) and CD147 (B) mRNA expressions in KMM-1
cells were inhibited by siRNA transfection. The cells were treated with each siRNA and incubated for up to 5 days. Cell lysates harvested on each
day were subjected to western blot analysis. Upper panel: siRNA-treated cells. Lower panel: control (untreated) cells. The siRNA-treated cells show
significant reductions in MCT1 or CD147. (C) Lactate incorporation is inhibited by MCT1 inhibition. The siRNA-treated cells (KMM-1) were analyzed
for lactate incorporation using 14C-lactate. To ensure the specificity of the analysis, cells were treated with radiolabeled lactate alone or combined
with unlabeled lactate (cold lactate) simultaneously. Note that lactate incorporation is significantly inhibited by the siRNA for MCT1, but not by
the siRNA for CD147.
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Warburg Effect. Because lactate does not seem to provide
to a large contribution for resting normal cells, this modal-
ity should provide efficacy that is relatively specific to can-
cer cells with minimal toxic effects toward normal tissues.
Conclusions
We present here that lactate is produced by MM cell
lines and stromal cells, and contributes to the survival of
such MM cells in autocrine or paracrine manners. Lac-
tate incorporation is dependent on MCT1. Suppression
of lactate incorporation by targeting MCT1 may provide
a novel therapeutic strategy for MM.
Materials and methods
Cells and cell culture
Human myeloma cell lines KMS-12BM (12BM) [30],
KMS-12PE (12PE) [30], U266 [31], RPMI8226 [32],KMM-1 [33], and KHM11 [34] were cultured in RPMI-
1640 containing 10% FBS at 37°C under 5% CO2. Usage
of isolated myeloma cells from bone marrow samples
were approved by Ethical Committee of Kumamoto
University.Inhibitors
Dichloroacetate (DCA) and α-cyano-4-hydroxycinnamic
acid (CHC) were purchased from Sigma-Aldrich (St
Louis, MO, USA), and dissolved in phosphate-buffered
saline and dimethyl sulfoxide (DMSO), respectively.Measurement of lactate
Lactate concentrations were evaluated using a lactate
meter (Lactate Pro2; Arkray, Kyoto, Japan), which elec-
tronically analyzed potassium ferrocyanide converted
from ferricyanide by lactate.
Figure 3 (See legend on next page.)
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Figure 3 Induction of apoptosis in myeloma cells by modulation of MCT1. (A) Induction of apoptosis by CHC. The myeloma cell lines KMS-12PE
(upper panels) and KMM-1 (lower panels) were treated with CHC at 0, 1.25, 2.5, or 5 mM for 24 h and then stained with Annexin V/PI for flow
cytometry analysis. Treatment with CHC induces Annexin V-positive (open bars) and PI-positive (filled bars) populations in a dose-dependent
manner. *p values for annexin V; **p values for PI. Representative raw data of the flow cytometry analyses are shown in the right panels. (B) CHC
does not induce apoptosis in normal PBMCs. PBMCs were treated with CHC as described for (A), and do not undergo apoptosis. (C) CD138
positive cells obtained from a MM patient were treated with CHC at 0, 1.25, 2.5, or 5 mM for 24 h and then stained with Annexin V/PI for flow
cytometry analysis. CHC induced apoptosis in myeloma cells obtained from a MM patient in a dose dependent manner. (D) MCT1 knockdown by
siRNA results in induction of apoptosis. KMM-1 cells were treated with each siRNA and incubated for up to 5 days. On day 5, cells were subjected
to Annexin V/PI staining. Amount of apoptotic cells are quantified and shown in the left panel. Results of FACS analysis are shown in the right
panel. Knockdown of MCT1 shows significant induction of apoptosis.
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RNA was extracted from myeloma cells using TRIzol re-
agent (Invitrogen, Carlsbad, CA, USA). cDNA synthesis
was performed using a SuperScript First-Standard Synthe-
sis System (Invitrogen) according to the manufacturer’s
protocol. Quantitative PCR analyses were performed with
Assay-on- Demand primers and Taqman Universal PCR
Master Mix Reagent (Applied Biosystems, Foster City,
NJ, USA). The samples were analyzed using an ECO™
Real-Time PCR System (Illumina, San Diego, CA, USA).
The ΔΔCt method was employed to analyze the relative
changes in gene expression as previously described [35],
with ACTB as a normalization control. The following
primers were used to quantify the expression of MCT1
and actin, respectively: SLC16A1 (Hs00161826_m1); and
ACTB (Hs99999903_m1).Figure 4 Combined treatment of CHC with DCA increases cell death. KMM
CHC and DCA, followed by Annexin V/PI analysis. CHC and DCA each indu
treatment (p < 0.0001, Annexin V or PI).Western blot analysis
Cell lysates were prepared using M-PER Mammalian
Protein Extraction Reagent (Pierce Biotechnology Inc.,
Rockford, IL, USA) after addition of Halt EDTA-free
phosphatase inhibitor cocktail and Halt protease inhibitor
cocktail (both from Pierce Biotechnology Inc.). Quantifica-
tion of total protein was performed with a Pierce BCA
Protein Assay Kit (Thermo Scientific, Waltham, MA,
USA), and equal amounts of protein were used for ana-
lysis. The cell lysates were separated in NuPAGE Bis-Tris
precast gels (Invitrogen) and transferred to PVDF mem-
branes. The membranes were blocked with 5% non-fat dry
milk dissolved in Tris-buffered saline (TBS) containing
0.5% Tween-20 (TBS-T) for 1 h at room temperature, and
then incubated with primary antibodies at 4°C for 18 h.
The following primary antibodies were used: anti-MCT11 cells were treated with CHC or DCA alone or the combination of
ce apoptosis alone, and the apoptosis is enhanced by the combined
Figure 5 Schematic model of lactate kinetics between myeloma
cells and bone marrow stromal cells. Lactate is produced by both
myeloma cells and bone marrow stromal cells, suggesting that it
acts as an autocrine and paracrine energy source. MCT1 may play an
important role as a gate for incoming lactate. Targeting of MCT1
may result in decreased incorporation of lactate, resulting in cell
death. PDH; pyruvate dehydrogenase, PDHK; pyruvate dehydrogenase
kinase, MCT1; monocarboxylate transporter1, DCA; Dichloroacetate
CHC; α-cyano-4-hydroxycinnamic acid.
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365501; 1:500), anti-CD147 (Cell Signaling Technology,
Beverly, MA, USA; #12314; 1:250), and anti-ACTB (Santa
Cruz Biotechnology; sc-8432; 1:1000). After washing
with TBS-T, the membranes were incubated with a
horseradish peroxidase-conjugated secondary antibody
(GE Healthcare, Little Chalfont, UK) for 1 h at room
temperature. The antibody-bound proteins were visual-
ized using ECL-prime Western Blotting Detection Re-
agent (GE Healthcare) and an LAS-1000 Bio-image
Analyzer (GE Healthcare).
The intensity of the western blot signals was quantified
by densitometry using image j.
Analysis of apoptosis
The myeloma cell lines were incubated in the presence of
DCA or CHC for 24 h. Apoptosis in the myeloma cell lines
was quantified by staining with Annexin V-allophycocyanin
(Molecular Probes, Eugene, OR, USA) and propidium iod-
ide (PI) (MBL, Nagoya, Japan). The samples were analyzed
by flow cytometry (FACSCalibur or FACSVerse; Becton
Dickson, San Jose, CA, USA).
RNA interference experiments
An oligonucleotide targeting human SLC16A1 (5′-CAG
CAGTATCCTGGTGAATAA-3′; siSLC16A1) was pur-
chased from Qiagen (Valencia, CA, USA). Transfectionswere performed using Hiperfect Transfection Reagent
(Qiagen) according to the manufacturer’s protocol.
Briefly, 2 × 105 KMM-1 cells in 100 μL of medium were
seeded into 24-well plates and transfected with 750 ng
of siSLC16A1 or control siRNA.
Lactate uptake assay
On day 2 after siRNA transfection, KMM-1 cells were
incubated in uptake buffer (10 mM HEPES, 5 mM
KCl, 150 mM NaCl, 1 mM MgCl2, pH 7.5) contain-
ing 14C-lactate (PerkinElmer, Waltham, MA, USA) for
1 h at 37°C. Uptake was stopped by incubating the cells
at 4°C, and the cells were washed twice using 200 μL of
uptake buffer. The cells were then lysed in 200 μL of
uptake buffer containing 1% SDS and the cell lysates
were collected into scintillation vials for quantifica-
tion of 14C-lactate uptake. To ensure selective incorpor-
ation of lactate, some cells were simultaneously treated
with 14C-lactate and unlabeled lactate (10 mM).
Statistical analysis
The data were analyzed statistically by Student’s t-test
using Statflex version 6 (Artech Co. Ltd., Osaka, Japan).
Values of p < 0.05 were considered statistically significant.
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